Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.

Hegedus B, Banerjee D, Yeh TH, Rothermich S, Perry A, Rubin JB, Garbow JR, Gutmann DH.

Cancer Res. 2008 Mar 1;68(5):1520-8. doi: 10.1158/0008-5472.CAN-07-5916.

2.

Neurofibromin in the brain.

Gutmann DH.

J Child Neurol. 2002 Aug;17(8):592-601; discussion 602-4, 646-51. Review.

PMID:
12403558
3.

Neurofibromatosis 1.

Lynch TM, Gutmann DH.

Neurol Clin. 2002 Aug;20(3):841-65. Review.

PMID:
12432832
4.

Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature.

Kocova M, Kochova E, Sukarova-Angelovska E.

BMC Endocr Disord. 2015 Dec 15;15:82. doi: 10.1186/s12902-015-0076-4. Review.

5.

Improving outcomes for neurofibromatosis 1-associated brain tumors.

Brossier NM, Gutmann DH.

Expert Rev Anticancer Ther. 2015 Apr;15(4):415-23. doi: 10.1586/14737140.2015.1009043. Epub 2015 Feb 5. Review.

PMID:
25652347
6.

Neurofibromatosis type 1 (NF1): diagnosis and management.

Ferner RE, Gutmann DH.

Handb Clin Neurol. 2013;115:939-55. doi: 10.1016/B978-0-444-52902-2.00053-9. Review.

PMID:
23931823
7.

[Molecular pharmacology on DNA methylating agent temozolomide].

Hirose Y, Sano H.

No Shinkei Geka. 2007 Feb;35(2):117-29. Review. Japanese. No abstract available.

PMID:
17310751
8.

Type I neurofibromatosis: a geno-oculo-dermatologic update.

Schnur RE.

Curr Opin Ophthalmol. 2012 Sep;23(5):364-72. doi: 10.1097/ICU.0b013e3283570127. Review.

PMID:
22871881
9.

Neurofibromatosis type 1: modeling CNS dysfunction.

Gutmann DH, Parada LF, Silva AJ, Ratner N.

J Neurosci. 2012 Oct 10;32(41):14087-93. doi: 10.1523/JNEUROSCI.3242-12.2012. Review.

10.

Genetic modeling of gliomas in mice: new tools to tackle old problems.

Hambardzumyan D, Parada LF, Holland EC, Charest A.

Glia. 2011 Aug;59(8):1155-68. doi: 10.1002/glia.21142. Epub 2011 Feb 8. Review.

11.

Recent advances in optic nerve glioma with a focus on the young patient.

Walker D.

Curr Opin Neurol. 2003 Dec;16(6):657-64. Review.

PMID:
14624073
12.

Mouse models of brain tumors and their applications in preclinical trials.

Fomchenko EI, Holland EC.

Clin Cancer Res. 2006 Sep 15;12(18):5288-97. Review.

13.

Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma.

Ricker CA, Pan Y, Gutmann DH, Keller C.

Front Oncol. 2016 Dec 20;6:259. doi: 10.3389/fonc.2016.00259. eCollection 2016 Dec 20. Review.

14.

[Pathology and treatment of autism spectrum disorders].

Kotajima-Murakami H, Sato A, Ikeda K.

Nihon Yakurigaku Zasshi. 2015 Apr;145(4):193-200. doi: 10.1254/fpj.145.193. Review. Japanese. No abstract available.

PMID:
25864830
15.

The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges.

Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill D.

Cancer Prev Res (Phila). 2008 Aug;1(3):161-6. doi: 10.1158/1940-6207.CAPR-08-0076. Review.

Supplemental Content

Support Center